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Abstract 
Sensitive and quantitative measurements of clinically relevant protein biomarkers, pathogens 
and cells in biological samples would be invaluable for disease diagnosis, monitoring of ma-
lignancy, and for evaluating therapy efficacy. Biosensing strategies using magnetic nanoparticles 
(MNPs) have recently received considerable attention, since they offer unique advantages 
over traditional detection methods. Specifically, because biological samples have negligible 
magnetic background, MNPs can be used to obtain highly sensitive measurements in minimally 
processed samples. This review focuses on the use of MNPs for in vitro detection of cellular 
biomarkers based on nuclear magnetic resonance (NMR) effects. This detection platform, 
termed  diagnostic  magnetic  resonance  (DMR),  exploits  MNPs  as  proximity  sensors  to 
modulate  the  spin-spin  relaxation  time  of  water  molecules  surrounding  the  molecular-
ly-targeted nanoparticles. With new developments such as more effective MNP biosensors, 
advanced conjugational strategies, and highly sensitive miniaturized NMR systems, the DMR 
detection capabilities have been considerably improved. These developments have also ena-
bled parallel and rapid measurements from small sample volumes and on a wide range of 
targets, including whole cells, proteins, DNA/mRNA, metabolites, drugs, viruses and bacteria. 
The DMR platform thus makes a robust and easy-to-use sensor system with broad applica-
tions in biomedicine, as well as clinical utility in point-of-care settings. 
Key words: biosensor; diagnostics; magnetic nanoparticle; microfluidics; nuclear magnetic reso-
nance. 
INTRODUCTION 
Rapid and sensitive characterization of rare bi-
omarkers in easily accessible bodily sources (e.g., fine 
needle aspirates, biopsies, and whole blood) will have 
significant impact on life sciences and clinical practice 
[1,  2].  Such  diagnostic  platforms  could  be  used  for 
screening and early diagnosis, comprehensive disease 
characterization  in  patients,  and  targeted  therapy 
based  on  personal  responses  to  treatments  [3,  4]. 
Clinical detection technologies ideally should 1) pro-
vide high sensitivity and specificity, 2) enable rapid 
measurements with minimal sample processing, and 
3) allow for multiple biomarker detection in a single 
parent  sample  (multiplexed  detection)  for  accurate 
diagnosis [5]. A number of sensors fulfilling some of 
these criteria have been developed based on optical [6, 
7], electronic [8, 9] or magnetic detection [10, 11]. The 
clinical adaptation of these systems, however, is still 
limited,  because  they  often  require  lengthy  sample 
purification or long assay times. 
Biosensing  strategies  based  on  magnetic  nano-
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particles (MNPs) have recently received considerable 
attention.  Magnetic  fields  experience  little  interfer-
ence from native biological samples as most biological 
entities have negligible magnetic susceptibilities, sim-
ilar  to  that  of  water  (~10–6).  Even  optically  turbid 
samples  thus  will  most  often  appear  transparent  to 
magnetic fields. However, when cells of interests are 
magnetically tagged, they will attain a high contrast 
against  the  biological  background.  To  detect  bi-
omarkers using MNPs, various detection technologies 
have been developed [12]. These include techniques 
that  use  magnetometers,  such  as  superconducting 
quantum  interference  device  (SQUID)  [13-15],  mag-
netoresistive  sensors  [16-19],  and  Hall  sensors  [20], 
which  directly  measure  the  magnetic  fields  from 
magnetically-labeled biological targets.  
We  have  recently  developed  a  new  magnetic 
sensing  platform,  diagnostic  magnetic  resonance 
(DMR) [21]. In contrast to direct detection of magnetic 
moments  with  magnetometers,  which  requires 
MNP-labeled targets to be closely positioned to the 
sensing  elements,  DMR  exploits  nuclear  magnetic 
resonance (NMR) as the detection mechanism. When 
placed  in  NMR  magnetic  fields,  MNPs  create  local 
magnetic fields, which change the relaxation rate of 
surrounding  water  molecules  [22].  The  mechanism 
simplifies and expedites the detection assays since the 
analytical signal is amplified and generated from the 
entire  sample  volume.  By  optimizing  MNPs  and 
miniaturizing  NMR  detectors,  the  DMR  detection 
sensitivity for various target types have been consid-
erably improved over the last few  years. These de-
velopments nowadays enable rapid and multiplexed 
detection  on  a  wide  range  of  targets  in  microliter 
sample volumes, including nucleic acids [23], proteins 
[21], drugs, bacteria [24], and tumor cells [25-28]. With 
the  recent  integration  of  bioorthogonal  targeting 
strategies [26, 29, 30] as well as accurate and real-time 
control of device temperature [31], the DMR platform 
has become more robust and sensitive, allowing op-
eration in clinical settings [25]. This review will report 
on the latest developments of new MNPs and DMR 
systems for improving detection sensitivities. Specific 
biomedical and clinical DMR applications will also be 
discussed.  
PRINCIPLE OF DMR ASSAY 
Due  to  their  small  size,  MNPs  assume  unique 
physical properties which are different from those of 
bulk materials. The most salient feature is the para-
magnetic  behavior  of  an  ensemble  of  small  MNPs, 
termed  superparamagnetism  [32].  For  most  magnetic 
materials (e.g., ferrite and iron), MNPs with diameter 
of < 20 nm have a single domain with magnetic mo-
ments  confined  in  a  particular  direction  defined  by 
magnetic  anisotropy.  At  sufficiently  high  tempera-
ture, thermal fluctuation can overcome the anisotropy 
barrier and spontaneously flip the magnetic moments 
of  MNPs  [33].  An  ensemble  of  MNPs  consequently 
displays negligible remnant magnetic moments in the 
absence of external magnetic fields, but the magnetic 
moments  grow  with  increasing  external  magnetic 
fields. This superparamagnetic property ensures that 
MNPs do not spontaneously aggregate under physi-
ological solutions. A MNP is typically comprised of 
an inorganic magnetic core and a biocompatible sur-
face coating, which can be modified with functional 
ligands to confer the MNP with molecular specificity. 
By producing local magnetic dipoles with strong 
spatial dependence, MNPs efficiently destroy the co-
herence in the spin-spin relaxation of water protons. 
The net effect is a change in magnetic resonance sig-
nal, which is measured as a shortening of the longi-
tudinal (T1, spin-lattice) and transverse (T2, spin-spin) 
relaxation times. The capacities of MNPs to decrease 
T2 and T1 are respectively defined as the transverse 
(r2)  and  the  longitudinal  (r1)  relaxivities.  Typically, 
because  the  transverse  relaxivities  (r2)  of  MNPs  are 
greater than their longitudinal relaxivities (r1), T2 is 
used for NMR-based biosensing applications. With a 
higher  r2 relaxivity,  fewer  numbers  of  nanoparticles 
are required to produce detectable T2 changes. 
DMR detection exploits targeted MNPs to mod-
ulate  the  spin-spin  T2  relaxation  time  of  biological 
samples.  Depending  on  the  size  of  the  target  bi-
omarker,  DMR  assays  can  take  two  forms.  For  the 
detection of small molecular analytes such as metab-
olites, oligonucloetides, and proteins, magnetic relax-
ation  switching  (MRSw)  effect  can  be  exploited. 
MRSw relies on the changes of organizational state of 
MNPs in solution. When MNPs cluster in solution, the 
aggregates  will  assume  different  r2  values,  causing 
corresponding  T2  changes.  MRSw  assays  are  per-
formed  without  removing  excess  unbound  MNPs 
(Fig. 1A), and thereby facilitate the detection of small 
molecules. For larger biological targets such as bacte-
ria, mammalian cells or cellular components, cell bi-
omarkers can be tagged  with functional MNPs and 
unbound MNPs are removed (Fig. 1B). This gain of 
magnetic moment (change of 1/T2) is proportional to 
the number of MNPs bound, and also indicative of the 
abundance of relevant biomarkers (Fig. 1C). 
MAGNETIC NANOPARTICLES AND 
THEIR RELAXATION PROPERTIES 
Many  different  types  of  MNPs  have  been  ex-
plored in an effort to maximize DMR detection sensi-
tivity. In addition to having good stability in aqueous Theranostics 2012, 2(1) 
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media,  newer  generations  of  MNPs  are  often  engi-
neered to have very high transverse relaxivity (r2) in 
order to induce pronounced T2 changes. According to 
the outer-sphere model, the transverse relaxivity of a 
MNP is proportional to  τd ·M2, where  τd is the resi-
dence time of water molecules around the particle and 
M  is  the  particle  magnetization  [34].  The  efforts  to 
enhance r2 were thus focused on synthesizing larger 
MNPs using magnetically stronger materials.  
 
 
Figure 1. DMR assay configurations. (A) Magnetic relaxation 
switching  (MRSw)  assays  detect  changes  in  the  organizational 
states of magnetic nanoparticles (MNPs) in solution. MRSw assays 
can be designed to cause forward switching, whereby molecular 
targets cross-link MNPs to induce MNP clustering, thus effecting a 
corresponding decrease in T2. Alternatively, the assays can cause 
reverse  switching,  where  enzymatic  cleavage  or  competitive 
binding of molecular targets disassembles pre-formed clusters to 
cause an increase in T2. (B) Magnetic tagging assays detect the 
presence  of  bound  MNPs  on  larger  biological  entities.  Bound 
MNPs impart a magnetic moment to tagged cells, leading to a 
decrease in T2 relaxation time. Unbound MNPs must be removed 
to ensure detection sensitivity. (C) This gain of magnetic moment 
(change of 1/T2) is proportional to the number of MNPs bound; 
shorter T2 indicates higher expression of the relevant biomarkers. 
(Reproduced with permission from [23]  [21]. Copyright 2002, 
2008 Nature Publishing Group.) 
Ferrite-based MNPs 
Among  different  ferrite  particles,  cross-linked 
iron  oxide  (CLIO)  nanoparticles  have  been  widely 
used for DMR applications, notably because of their 
excellent  stability  and  biocompatibility  [35].  CLIO 
nanoparticles contain a superparamagnetic iron oxide 
core (3–5 nm monocrystalline iron oxide) composed of 
ferrimagnetic  magnetite  (Fe3O4)  and/or  maghemite 
(γFe2O3). The metallic core is coated with biocompat-
ible dextran, before being cross-linked and function-
alized with primary amine. Amine-terminated CLIO 
nanoparticles have an average hydrodynamic diame-
ter of 25-40 nm, approximately 40-80 amines per na-
noparticle for bioconjugation, and a r2 of ~50 s–1.mM–1 
[Fe] [23, 36].  
To  enhance  the  magnetization  of  ferrite  nano-
particles,  two  main  strategies  have  been  employed, 
namely  magnetic  doping  and  nanoparticle  sizing. 
Doping of ferrite with ferromagnetic elements such as 
manganese (Mn), cobalt (Co) or nickel (Ni) [24, 37, 38] 
has been shown to improve the MNP magnetization. 
Among the singly-doped ferrite MNPs, MnFe2O4 na-
noparticles  have  the  highest  magnetization  and  r2 
value, on account of their electron spin configurations, 
followed  by  FeFe2O4,  CoFe2O4,  and  NiFe2O4.  More 
recently, it has been demonstrated that magnetization 
can be further enhanced via additional Zn2+ doping in 
MnFe2O4 nanoparticles [39]. In addition, nanoparticle 
magnetization is known to increase with particle size 
[40]. Ideally, each magnetic spin within a bulk mag-
netic  material  would  align  parallel  to  the  external 
magnetic  field.  However,  in  the  nanoscale  regime, 
surface spins tend to be tilted (spin canting), a feature 
that decreases the overall magnetic  moment. By in-
creasing the MNP size, this surface effect is reduced to 
increase  the  overall  magnetization;  the  increase  in 
particle size further enhances the particle r2.  
Both magnetic doping and sizing strategies were 
employed by our laboratory to produce MnFe2O4 na-
noparticles with superior r2 relaxivity [28]. These par-
ticles  were  synthesized  by  reacting  iron  (III)  acety-
lacetonate [Fe(acac)3], manganese (II) acetylacetonate 
[Mn(acac)2] and 1,2-hexadecanediol at high tempera-
ture (300 °C). Through a seed-mediated growth ap-
proach,  the  magnetic  core  diameter  was  increased 
from 10 nm to 12, 16, or 22 nm. MnFe2O4 nanoparticles 
with  diameter  ≤  16  nm  were  found  to  be  highly 
monodisperse and superparamagnetic at 300 K (Fig. 
2A).  The  MNPs  were  subsequently  rendered  wa-
ter-soluble  using  the  small  molecule  me-
so-2,3-dimercaptosuccinic  acid  (DMSA)  [24,  40,  41]. 
Due to DMSA‟s small size, the hydrodynamic diame-
ter of MnFe2O4 nanoparticles was found to be smaller 
than that of CLIO nanoparticles, despite their larger Theranostics 2012, 2(1) 
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magnetic core. More importantly, these MnFe2O4 na-
noparticles assumed high relaxivities with  r2 values 
reaching  420  s–1.mM–1[metal]  (equal  to  6×10−14  L·s−1 
per  particle),  more  than  8  times  greater  than  CLIO 
nanoparticles  in  metal  basis  (50  s–1.mM–1[metal]  or 
7×10−16 L·s−1 per particle) [28].  
Fe-core MNPs 
Ferromagnetic  metals,  rather  than  their  corre-
sponding  oxides,  have  been  suggested  as  an  ideal 
constituent  for  MNPs  for  their  superior  magnetiza-
tion. This motivates the creation of Fe-core MNPs to 
achieve high r2 relaxivities [42, 43]. However, because 
Fe cores are extremely reactive, monometallic MNPs 
typically require protective layers to prevent progres-
sive oxidation.  
Recently,  a  unique  16  nm  Fe-core/ferrite  shell 
MNP, known as “cannonball”, has been developed for 
DMR applications (Fig. 2B) [44]. These structures are 
unique in that they contain elemental iron as core (not 
iron oxide) and a protecting oxide shell. These can-
nonballs were synthesized by thermally decomposing 
iron (0) pentacarbonyl [Fe(CO)5] to form the Fe core. A 
protective ferrite shell was formed by controlled oxi-
dation with oxygen gas; this resulted in a thinner shell 
and retained a larger Fe core. The cannonballs were 
then coated with DMSA as described above. Because 
of their large Fe core, superparamagnetic cannonballs 
showed high magnetization (763 kA·m–1). The relax-
ivity of cannonballs is similar to that of MnFe2O4 na-
noparticles (6×10−14 L·s−1 per particle) (Fig. 2D). 
 
 
Figure 2. Higher r2-relaxivity MNPs developed to enhance in vitro detection sensitivity. (A) Transmission electron micro-
graph (TEM) images of manganese-doped ferrite nanoparticles (MnFe2O4). These nanoparticles have narrow size distribution and high 
crystallinity, and were synthesized using a seed-growth method to produce 10, 12, 16, and 22 nm nanoparticles. (B) TEM image of ele-
mental iron (Fe) core/ferrite shell magnetic nanoparticles (CB; cannonballs). These particles have a large Fe core (11 nm) passivated with 
a thin ferrite shell (2.5 nm) that is produced through controlled oxidation. (C) TEM image of Fe core/ferrite shell magnetic nanoparticles 
with tunable core size and shell composition. The Fe cores were enlarged into a thermally stable ferromagnetic state to increase the 
overall magnetization. Protective ferrite shells were then grown onto the cores, without oxidizing the cores, and metal-doped to further 
enhance magnetization. The resultant particles displayed hysteresis with negligible coercivity. (D) Comparison of size, r2 relaxivity, and 
saturated magnetization of various doped-ferrite and elemental Fe-based nanoparticles. CLIO, cross-linked iron oxide; MION, mono-
crystalline iron oxide. (Adapted with permission from [28] Copyright 2009 National Academy of Sciences, USA. Reproduced with 
permission from [44]. Copyright 2009 John Wiley and Sons, Inc. Reproduced with permission from [45] Copyright 2011 John Wiley and 
Sons, Inc.) Theranostics 2012, 2(1) 
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Figure 3. Bioorthogonal nanoparticle detection (BOND) strategy for DMR detection. Schematics showing the conjugation 
chemistry and coupling between antibody and nanoparticle. Antibodies against biomarkers were modified with trans-cyclooctene (TCO) 
and used as scaffolds to couple more tetrazine (Tz) modified nanoparticles onto live cells. The strategy is fast, catalyst-free, specific even 
in complex biological environment, and amplifies biomarker signals. (Reproduced with permission from [26]. Copyright 2010 Nature 
Publishing Group.) 
 
We  have  further  advanced  Fe-core  MNPs  by 
developing a new synthetic approach for tunable core 
size and shell composition [45]. These new generation 
MNPs  consist  of  an  Fe  core  and  an artificial  ferrite 
shell (Fe@MFe2O4, M = Fe, Mn, Co). The Fe cores were 
enlarged into a thermally stable ferromagnetic state to 
increase the overall magnetization. Instead of tradi-
tionally oxidizing the Fe core to form the shell, pro-
tective ferrite shells were grown onto the cores and 
metal-doped  to  further  enhance  magnetization.  The 
resultant particles displayed a unique magnetic fea-
ture, the presence of hysteresis with negligible coer-
civity. Further analysis revealed a novel magnetiza-
tion process wherein the shell effectively reduces the 
coercivity of the ferromagnetic cores by leading the 
magnetization process at small magnetic fields. The 
resulting  particles,  especially  Fe@MnFe2O4  MNPs 
(Fig. 2C) attained high saturation magnetization (796 
kA·m–1)  and  r2  (7×10−14  L·s−1  per  particle;  430 
s–1·mM–1[metal]) (Fig. 2D) but with negligible rema-
nence  to  prevent  inter-particle  aggregations.  When 
applied  for  DMR  assays,  these  Fe@MnFe2O4  MNPs 
achieved superior performance, capable of detecting 
picomolar  avidin  and  single  cancer  cells  in  whole 
blood samples. 
Bioorthogonal nanoparticle detection (BOND) 
In addition to the previous strategies to enhance 
MNP  relaxivities,  surface  modification  of  particles 
and  novel  targeting  approach  also  improve  DMR 
sensing  capacities.  Bioorthogonal  cycloaddition  be-
tween a 1,2,4,5-tetrazine (Tz) and a trans-cyclooctene 
(TCO) is a fast and chemoselective reaction that does 
not require a catalyst, and can be used for small mol-
ecule labeling in serum [46, 47]. Recently, this chem-
istry has been successfully adapted to MNP targeting, 
and has been shown to improve nanoparticle binding 
valency  and  detection  sensitivity.  Termed 
„bioorthogonal  nanoparticle  detection‟  (BOND),  this 
novel targeting platform employs Tz and TCO as the 
coupling  agents  [26].  Specific  antibodies  are  first 
modified  with  TCO;  once  bound  to  cellular  bi-
omarkers  of  interest,  the  TCO-modified  antibodies 
facilitate  the  coupling  of  Tz-modified  nanoparticles 
(Fig. 3). Because of the small size of the coupling rea-
gents,  their  high  multiplicity  on  antibod-Theranostics 2012, 2(1) 
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ies/nanoparticles  resulted  in  higher  nanoparticle 
binding to cells. This not only amplifies the biomarker 
signals but also significantly improves the detection 
sensitivity of DMR assays. Moreover, this platform is 
broadly-applicable  for  both  extracellular  and  intra-
cellular biomarker detection, and scalable for clinical 
uses [27, 48]. Already, BOND has been successfully 
adapted for DMR molecular profiling of experimental 
cellular samples [26] and clinical fine needle aspirate 
samples  [25].  Recently,  we  have  developed  newer 
two-step detection schemes based on complementary 
oligonucleotide approaches [29], alternative cycload-
dition chemistries [49] and cyclodextrin/adamantine 
supramolecular interactions [30]. 
MINIATURIZED NMR SYSTEMS 
A key to sensitive detection in DMR is the min-
iaturized  nuclear  magnetic  resonance  (µNMR)  sys-
tems  (Fig.  4)  [21].  The  miniaturization  of  the  NMR 
device brings distinctive advantages. First, it lowers 
the detection limit by reducing the sample volumes 
and  hence  effectively  increasing  analyte  concentra-
tions [50]. Second, miniaturized NMR probes (coils) 
produce  much  stronger  radio-frequency  (RF)  mag-
netic  fields  per  unit  current,  leading  to  higher  sig-
nal-to-noise per unit sample volume [51]. Third, with 
smaller  RF  coils,  the  requirement  for  spatial  homo-
geneity  of  static  magnetic  fields  becomes  less  strin-
gent, making it possible to use small, portable mag-
nets [21].  
The  first  prototype  (µNMR-1;  Fig.  4a)  was  de-
signed to test the feasibility of miniaturization. The 
system consisted of a microfabricated NMR probe, a 
small permanent magnet (B = 0.5 T), custom-designed 
NMR electronics, and a microfluidic network [21]. The 
probe had multiple planar microcoils (a 2 × 4 array) to 
enable parallel detection. In this system, the coils ex-
cite  biological  samples  by  emitting  RF  pulses,  and 
subsequently receive resulting NMR signals. The mi-
crofluidic networks provide efficient mixing between 
the samples and MNPs and guide the samples to eight 
different planar coils. To compensate for the magnetic 
field inhomogeneity from the small permanent mag-
net,  Carr-Purcell-Meiboom-Gill  (CPMG)  spin-echo 
pulse sequences were used for transverse (T2) relaxa-
tion time measurements. To generate versatile pulse 
sequences while  using  minimal electronic parts,  we 
devised a new circuit schematic for NMR electronics, 
that has served as a blueprint for subsequent NMR 
systems.  
The second prototype (µNMR-2) was designed 
to  improve  the  DMR  detection  sensitivity  by  opti-
mizing the NMR probe (Fig. 4B) [28, 44]. We selected 
wire-wound solenoidal coils as the probe format, as 
they could produce more homogeneous RF magnetic 
fields and have less electrical resistance. The overall 
signal-to-noise ratio (SNR) was further enhanced by 
fully embedding the coils into the fluidic system. In 
brief, solenoidal coils were prepared by winding in-
sulated  wires  around  a  polyethylene  tube.  The 
coil-tube assembly was placed on a template for mi-
crofluidic systems, and cast-molded by pouring pol-
ydimethylsiloxane  (PDMS).  After  PDMS  curing,  the 
tube was extracted to open up the entire coil-bore for 
fluidic access for high filling factor (≈ 1). Combined 
with lower electrical noise of the coils, the µNMR-2 
showed 10-fold higher mass detection sensitivity than 
µNMR-1, and enabled highly sensitive detection (sin-
gle mammalian cells, a few bacteria). In parallel with 
the probe development, we also strategized to min-
iaturize the entire NMR system. Particularly, we cus-
tom-designed  a  CMOS  (complementary-metal-oxide 
semiconductor) chip (1.4 × 1.4 mm2 ) that integrates all 
NMR electronics (Fig. 4C) [52, 53]. The whole NMR 
setup could be packaged as a mobile hand-held de-
vice, making µNMR-2 the world‟s smallest NMR sys-
tem.  
 Most recently, we have developed a third gen-
eration µNMR-3 device optimized for routine clinical 
applications  (Fig.  4D)  [31].  A  major  challenge  in 
moving µNMR from a basic science laboratory to a 
clinical environment has been the system‟s inherent 
sensitivity to temperature. The latter originates from 
the  temperature-dependent  fluctuation  of  the  mag-
netic field generated by the permanent magnet. These 
fluctuations lead to drifts in the NMR frequency, re-
sulting in an artifact in the measured T2 values. In a 
laboratory setting, the problem can be addressed by 
controlling  the  environmental  and  system  tempera-
tures. Such a solution, however, significantly increas-
es the cost and size of the µNMR system, undermin-
ing its use for point-of-care applications. In the new 
µNMR-3,  we  solved  this  problem  through  an  elec-
tronic approach: we implemented a feedback routine 
that  automatically  tracks  temperature  changes  and 
correspondingly  reconfigures  the  measurement  set-
tings.  This  solution  guarantees  reliable  and  robust 
DMR measurements. For example, when the tracking 
routine  was  turned  off,  T2  values  fluctuated  up  to 
200% of its initial value in a typical laboratory setting. 
With the tracking on, however, T2 variations consid-
erably decreased (< 1%; Fig. 4D right).  
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Figure  4.  Miniaturized  devices  developed  for  DMR  biosensing.  (A) The first-generation miniaturized device (µNMR-1) to 
measure relaxation times of biological samples consists of an array of microcoils for NMR measurements, microfluidic networks for 
sample handling and mixing, miniaturized NMR electronics and a portable permanent magnet to generate a polarizing magnetic field. (B) 
The second-generation (µNMR-2) consists of a solenoidal coil embedded in a microfluidic device. As compared to the previous genera-
tion, this improved device has a higher filling factor, better signal-to-noise ratio, and reduces sample volume requirement to ~1 μl. (C) 0.1 
kg “palm” µNMR-2 system is 20× lighter and 30× smaller than previous generation. To achieve this significant size reduction, a small 0.56 
T magnet was used. To compensate for the signal reduction from the smaller magnet, this device incorporates a new RF transceiver fully 
integrated in the 0.18-μm CMOS. (D) The latest generation of µNMR is equipped with the capability to automatically track and com-
pensate for temperature changes, ensuring robust and reliable T2 measurements. With the temperature compensation turned on, the 
measured T2 values of the same sample showed <1% variation, whereas T2 values fluctuated >200% without such scheme (right). The new 
system communicates with mobile devices (smartphones, tablet computers) for easy system control and data logging. (Reproduced with 
permission from [24]. Copyright 2008 Nature Publishing Group. Reproduced with permission from [28].  Copyright 2009 National 
Academy of Sciences, USA. Reproduced with permission from [52]. Copyright 2010 IEEE. Reproduced with permission from [31]. 
Copyright 2011 RSC Publishing.) 
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The  µNMR-3  features  other  important  aspects 
for practical use. Unlike the previous generations of 
µNMR, small-form factor NMR electronics (20 × 12 × 
5 cm3) were assembled using off-the-shelf integrated 
circuit  (IC)  chips  (e.g.,  microcontrollers,  RF  synthe-
sizers), reducing the cost of the system (<$200) and 
enhancing  the  programmability.  Moreover,  the 
µNMR-3  interfaces  with  mobile  devices  (e.g.,  iPh-
one™, iPAD™) for its operation. This maximizes the 
portability  of  µNMR-3  and  improves  us-
er-friendliness; medical personnel can obtain sample 
data promptly via customized DMR applications and 
achieve  real-time  data  logging/sharing  over  an  en-
crypted wireless network in a remote clinical site. We 
have recently employed this system in several clinical 
trials of cancer detection and profiling.  
To date, the DMR platform has been successfully 
applied to sensitively quantify a wide range of bio-
logical targets including DNA/mRNA [23, 54], pro-
teins [21, 23, 55], enzyme activities [23, 56, 57], small 
molecules/drugs [58, 59], bacteria [21, 44], viruses [60] 
and mammalian tumor cells [21, 25, 26, 28]. As de-
scribed previously, the detection mode of DMR de-
pends on the size of its targets. For small targets such 
as  oligonucleotides,  proteins and  other  small  mole-
cule  metabolites,  MRSw  sensing  has  been  used.  In 
these examples, MNPs were conjugated with target-
ing ligands to function as multivalent sensors. In the 
presence  of  the  analytes,  MNP  binding  and  subse-
quent clustering causes corresponding T2 changes to 
indicate the quantity of the targets. Moreover, such 
assay strategy can also be used to analyze enzymatic 
activities. For example, specific MNPs have been de-
signed to assess human telomerase (hTERT) activity 
by hybridizing with the 30-base pair telomeric repeat 
sequences  produced  by  hTERT  activity  [54].  More 
recently, myeloperoxidase (MPO) sensors were gen-
erated  by  attaching  phenol-containing  molecules, 
such as dopamine or serotonin, to CLIO nanoparticles 
[61].  In  the  presence  of  peroxidase  activity,  tyroxyl 
radicals were formed to cross-link the nanoparticles. 
Using  this  assay  configuration,  leukocyte-derived 
MPO  has  been  shown  to  play  a  critical  role  in  the 
pathogenesis of atherosclerotic plaques. 
CANCER DETECTION AND PROFILING 
Sensitive detection and rapid profiling of tumor 
cells in unprocessed biological samples will have sig-
nificant impact on both biomedical research and clin-
ical  practice.  DMR  molecular  profiling  of  cancer 
markers  (HER2/neu,  EGFR,  and  EpCAM)  on  mam-
malian  cells  was  initially  demonstrated  using  the 
first-generation DMR device (µNMR-1) [21]. In these 
early experiments, CLIO nanoparticles were directly 
conjugated  to  monoclonal  antibodies.  Using  the  se-
cond-generation  μNMR-2  and  the  highly  magnetic 
MnFe2O4 nanoparticles,  cellular  detection  sensitivity 
was remarkably improved [28].  
 
Figure 5. Tumor cell detection and profiling with DMR. (A) The detection sensitivity of DMR was approximately two cells (in 1 µl 
sample volume) using the improved µNMR-2 device (Figure 4B) and the highly magnetic MnFe2O4 nanoparticles (Figure 2A) , making this 
detection platform superior to current clinical methods (cytology and histology). (B and C) Different human breast cancer cells with 
varying expression of HER2/neu and control cells were labeled with MnFe2O4 nanoparticles. DMR measurements correlated well with 
standard molecular analyses such as flow cytometry, Western blot and immunofluorescence, but required substantially fewer cells. 
(Reproduced with permission from [28]. Copyright 2009 National Academy of Sciences, USA.) Theranostics 2012, 2(1) 
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Notably,  as  shown  in  Fig.  5A,  the  detection 
threshold  was  reduced  to  approximately  single-cell 
level, far surpassing the sensitivity of other conven-
tional clinical methods. There was also a good corre-
lation  between  DMR  and  other  standard  methods 
(e.g., microscopy, flow cytometry and Western blot-
ting; Figs. 5B, C).  
Through  these  sets  of  early  experiments,  the 
DMR detection platform was shown to not only re-
quire  far  fewer  cells  than  standard  alternative  ap-
proaches, but also produce results much faster (< 15 
minutes).  In  addition,  the  DMR  platform  is  ideally 
suited  for  rapid  multi-target  detection,  since  it  can 
make  measurements  on  few  cells  in  small  sample 
volumes  and  in  a  multiplexed  manner.  The  use  of 
BOND strategy has further advanced DMR profiling 
capabilities. As a universal labeling approach, BOND 
simplifies the preparation of the targeted MNPs for 
multiplexing  and  amplifies  nanoparticle  binding  to 
cells.  As  a  proof-of-principle  analysis,  cancer  cells 
were targeted with CLIO nanoparticles via BOND. At 
a  low  cell  count  (~1000  cells  per  sample),  parallel 
DMR measurements could be performed rapidly [26].  
Through the remarkable integration of the DMR 
and BOND technologies, this chip-based NMR detec-
tion  platform  has  been  recently  applied  in  clinical 
trials of cancer cell profiling [25]. Single fine-needle 
aspirates were obtained from a cohort of 50 patients 
and analyzed directly with the DMR platform for re-
al-time quantification of multiple protein markers. A 
surprising degree of heterogeneity in protein expres-
sion  both  across  the  different  patient  samples  and 
even with the same tumor was observed (Fig. 6A).  
 
Figure 6. Clinical applications of DMR in tumor diagnostics. Single fine-needle aspirates were obtained from a cohort of patients, 
and were tagged via the BOND strategy for DMR detection. (A) Real-time quantification of multiple protein markers with the DMR 
platform indicates a high degree of heterogeneity in protein expression both across the different patient samples and even with the same 
tumor. (B) Using a four-protein signature (HER2/neu, EGFR, EpCAM and Muc-1), the DMR platform reports a 96% accuracy for estab-
lishing a cancer diagnosis, surpassing conventional clinical analyses by immunohistochemistry. (Reproduced with permission from [25]. 
Copyright 2011 American Association for the Advancement of Science AAAS.) Theranostics 2012, 2(1) 
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This first clinical study indicated that 1) single 
fine-needle  aspirates  contain  sufficiently  high  num-
bers of cells to enable real-time quantitative analysis 
of  many  molecular  markers  with  DMR;  2)  using  a 
four-protein  signature  (HER2/neu,  EGFR,  EpCAM 
and Muc-1), the DMR platform reports a 96% accu-
racy  for  establishing  a  cancer  diagnosis,  surpassing 
conventional clinical analyses by immunohistochem-
istry (Fig.  6B). Based on these results, a number of 
additional  clinical  trials  are  currently  ongoing.  The 
DMR  platform  thus  represents  a  novel  system  for 
real-time  molecular  diagnostics  close  to  the  patient 
bedside,  and  a  valuable  tool  for  investigating  and 
establishing  tumor  heterogeneity  and  therapeutic 
drug targeting. 
CONCLUSIONS AND PERSPECTIVES 
The  DMR  biosensor  platform  seamlessly  inte-
grates several cutting-edge technologies, namely na-
nomaterials, bioconjugation chemistry and microfab-
rication. As a novel technique, it offers a number of 
synergistic advantages such as high detection sensi-
tivity, rapid target measurement with minimal sam-
ple processing, and the ability to profile a wide range 
of targets in a multiplexed manner from small sample 
volumes. With recent developments such as the ad-
vent  of  chip-based  μNMR  devices,  optimized  mag-
netic nanomaterials and advanced conjugation tech-
niques,  the  DMR  technology  is  a  highly  attractive 
platform to enable low-cost, and sensitive biomolec-
ular detection in a point-of-care setting.  
In addition to having significant practical use for 
quantitative  and  molecular  analyses  in  biomedical 
research,  the  DMR  platform  also  has  far-reaching 
impact on clinical disease management. The capabil-
ity to detect and molecularly profile cells with mini-
mal false negatives would accelerate the advance of 
personalized  treatment,  by  providing  valuable  in-
formation  on  cellular/molecular  signature  of  indi-
vidual patients. We further envision a broader appli-
cation of the DMR platform in global healthcare. As 
DMR sensing does not require extensive sample puri-
fication as do optical methods, and the platform can 
be packaged as a portable device, the system is thus 
well-suited for rapid and point-of-care testing, espe-
cially in resource-limited primary clinics. 
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